Boehringer ingelheim

Index
Globenewswire

Boehringer Ingelheim Strengthens Antibody-drug Conjugate Portfolio with New NBE Therapeutics R&D Center in Basel

Globenewswire

Boehringer Ingelheim Reaches More Patients in 2024 and Prepares New Medicine Launches

Globenewswire

Boehringer Ingelheim Launches New Trivalent Poultry Vaccine, Includes Protection Against H5 Avian Influenza

Globenewswire

Boehringer Ingelheim and Partners Start Clinical Development of a First-in-class, Inhaled Gene Therapy for People with Cystic Fibrosis

Globenewswire

Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-mutant Advanced Non-small Cell Lung Cancer

Globenewswire

Boehringer’s Nerandomilast Meets Primary Endpoint in Phase III Study FIBRONEER™-ILD, in Progressive Pulmonary Fibrosis

Globenewswire

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Globenewswire

Boehringer’s Focus on Health Equity Drives Significant Upgrade in Access to Medicine Index Ranking

Globenewswire

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative Join Forces to Combat Vision Loss from Diabetes

Globenewswire

Boehringer Ingelheim and WHO Foundation Join Forces to Promote Equitable Access to Healthcare and Increase Efforts for Suicide Prevention

Globenewswire

Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two Phase III Trials in MASH for Survodutide

Globenewswire

Boehringer Ingelheim Partners with NCD Alliance to Target Non-Communicable Diseases in Underserved Communities

Globenewswire

Boehringer Ingelheim Expands Cancer Research at its Vienna Site

Globenewswire

Boehringer’s Nerandomilast Meets Primary Endpoint in Pivotal Phase-III FIBRONEER™-IPF Study

Globenewswire

Boehringer’s Zongertinib Shows Encouraging Efficacy and Tolerability Profile in Previously Treated HER2 Mutated Lung Cancer Patients

Globenewswire

Boehringer Ingelheim Announces Plans to Advance Potential New Treatment for Geographic Atrophy, Following Positive Phase I Results

Globenewswire

Boehringer Ingelheim Acquires Saiba Animal Health, Adding Innovative Technology Platform to its Pet Therapeutics R&D Portfolio

Globenewswire

Boehringer Ingelheim to Unveil Groundbreaking Oncology Research at WCLC, Demonstrating Strength of Portfolio

Globenewswire

CHMP Adopts Positive Opinion Recommending Approval of New and Expanded Indications for SPEVIGO®

Globenewswire

First half of 2024: Boehringer Ingelheim Progresses Pipeline at Pace and Reaches Major Milestones

Globenewswire

Boehringer Ingelheim Produces its Own Green Energy

Globenewswire

Outdated Perceptions and Practices Fuelling Mental Health Crisis, New Economist Impact Study Reveals

Globenewswire

Boehringer Ingelheim Shares Positive Results from the First Study Worldwide in Diabetic Macular Ischemia

Globenewswire

Less than Half of Veterinary Professionals Feel Their Profession is Appreciated

Globenewswire

Boehringer Ingelheim Reports Strong Growth in 2023 and Accelerates Late-stage Pipeline